Tenax Therapeutics, Inc. (TENX) Financials
TENX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 123.2 million | 8.5 million |
| Dec. 31, 2025 | 104.2 million | 7.2 million |
| Sept. 30, 2025 | 102.8 million | 6.6 million |
| June 30, 2025 | 105.9 million | 2.5 million |
TENX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -9.3 million | 2.8 million |
| Dec. 31, 2025 | -13.4 million | -14.4 million |
| Sept. 30, 2025 | -9.2 million | 5.6 million |
| June 30, 2025 | -6.3 million | 4.6 million |
TENX Net Income
No data available :(
TENX Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 118.8 million | - | - |
| Dec. 31, 2025 | 97.6 million | - | - |
| Sept. 30, 2025 | 99.4 million | - | - |
| June 30, 2025 | 105.5 million | - | - |
TENX Shares Outstanding
TENX Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | - | 11.5 million | 5.0 million | - |
| Dec. 31, 2025 | - | 10.5 million | 5.9 million | - |
| Sept. 30, 2025 | - | 10.3 million | 6.5 million | - |
| June 30, 2025 | - | 6.1 million | 5.7 million | - |
TENX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | - | - |
| Dec. 31, 2025 | - | - |
| Sept. 30, 2025 | - | - |
| June 30, 2025 | - | - |
TENX
Price: $14.53
52 week price:
Earnings Per Share: -1.41 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 57000
Ebitda: -44.8 millionMarket Capitalization: 265.9 million